Abstract
This randomized, investigator-masked, multicenter, parallel-design trial compared the IOP-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in African Americans with glaucoma or ocular hypertension. After a washout of all ocular hypotensive agents, patients were assigned to bimatoprost once daily (n=16) or travoprost once daily (n=15) for 3 months. Study visits were at baseline and at months 1, 2, and 3. Primary outcome measures were the percentage of patients who achieved selected target pressures and the mean reduction in IOP from baseline at month 3. Both drugs comparably lowered IOP, but bimatoprost was more likely than travoprost to allow achievement of every target pressure from 12 to 19 mm Hg at month 3. After 3 months, the mean IOP reduction from baseline was 8.4 mm Hg (34%) in the bimatoprost group and 7.9 mm Hg (30%) in the travoprost group. These results are being evaluated further in a larger clinical trial.
Similar content being viewed by others
References
Marshall EC. Racial differences in the presentation of chronic open-angle glaucoma.J Am Optom Assoc. 1989;60:760–777.
Sommer A, Tielsch JM, Katz J, et al, for the Baltimore Eye Survey Research Group. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans.Arch Ophthalmol. 1991;109:1090–1095.
Palmissano P, Hynes M, Mueller L. Glaucoma and race: a case for screening in Connecticut.Conn Med. 2000;64:75–78.
Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore.N Engl J Med. 1991;325:1412–1417.
Javitt JC, McBean AM, Nicholson GA, et al. Undertreatment of glaucoma among black Americans.N Engl J Med. 1991;325:1418–1420.
AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups.Am J Ophthalmol. 2001;132:311–320.
Higgenbotham E, Schuman J, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Bimatoprost Study Groups I and II.Arch Ophthalmol. 2002;120:1286–1293.
Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.Am J Ophthalmol. 2001;132:472–484.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Noecker, R.J., Earl, M.L., Mundorf, T. et al. Bimatoprost 0.03% versus travoprost 0.004% in Black Americans with glaucoma or ocular hypertension. Adv Therapy 20, 121–128 (2003). https://doi.org/10.1007/BF02850259
Issue Date:
DOI: https://doi.org/10.1007/BF02850259